The prognostic value of time needed on dialysis in patients with delayed graft function
|
|
- Sharon Williams
- 7 years ago
- Views:
Transcription
1 NDT Advance Access published October 28, 2013 Nephrol Dial Transplant (2013) 0: 1 6 doi: /ndt/gft412 Original Article The prognostic value of time needed on dialysis in patients with delayed graft function Caitlyn Marek 1,2, Benjamin Thomson 3, Ahmed Shoker 2, Patrick P. Luke 3 and Michael A.J. Moser 1,2 Correspondence and offprint requests to: Michael A.J. Moser; mike.moser@usask.ca 1 Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada, 2 Saskatchewan Renal Transplant Program, St. Paul s Hospital, Saskatoon, SK, Canada and 3 Multi-Organ Transplant Program, London Health Sciences Centre, Schulich School of Medicine, Western University, London, ON, Canada Keywords: delayed graft function, dialysis, kidney transplantation, prognosis, time needed on dialysis ABSTRACT Introduction. We hypothesize that in patients with delayed graft function (DGF), the need for a longer time needed on dialysis (TND) post-kidney transplant is associated with poorer long-term function and an increase in complications. Methods. This was a retrospective chart review involving collaboration between Western University (WU) Renal Transplant Program of London, Ontario and the Saskatchewan renal transplant program (SRTP). A total of 774 patients (567 WU and 207 SRTP) received kidney transplants between 2004 and 2011, of which 83 patients with deceased donor transplants (59 WU and 24 SRTP) developed DGF, defined as the need for dialysis in the first week posttransplant. Results. Patients with DGF were divided into three groups depending on TND [group 1: <7 days (n = 52), group 2: 7 14 days (n = 13) and group 3 (n = 18): >14 days]. The creatinine clearance (CrCl) at 30 days (42.5, 33.8, 20.0 cc/min; P < 0.001) and 1 year (56.7, 49.2, 37.3 cc/min, P = 0.031) were significantly different between the three groups. Multivariate regression analysis identified length of TND posttransplant (β = 0.5, P < 0.001) and donation after cardiac death (DCD) donor (β = 19.5, P < 0.001) as the most significant predictors of CrCl at 1 year in these patients with DGF. DCD kidneys with DGF had a higher CrCl at 1 year and fewer readmissions in the first year compared with non-dcd kidneys with DGF. Discussion. Our study suggests that increased TND is associated with worse CrCl at 1 year. The data also support the hypothesis of a different mechanism for DGF in DCD and non-dcd kidneys. INTRODUCTION In the early posttransplant period, some kidneys recover quickly from delayed graft function (DGF), while others can take weeks before resuming function [1]. Overall, the longterm outcomes are less favorable for grafts that have initial DGF [2, 3]. Yet, little has been written about the long-term prognosis of those kidneys that take longer to wake up after transplant, particularly in the era of donation after cardiac death (DCD) kidney transplants. A review of the literature shows that only a few studies have examined time needed on dialysis (TND) as a factor in longterm graft function. An early study used a unique definition of DGF that was independent of the need for dialysis (time to attain an estimated glomerular filtration rate (egfr) of 10 ml/min) [4]. In their study, kidneys requiring >6 days to cross this threshold of egfr were shown to have a poorer long-term graft survival. In 2009, a small study suggested that serum creatinine at 1 year was adversely affected by a longer DGF duration [5]. A more recent study showed that the need for only a single dialysis treatment after transplant was not associated with the worse outcomes seen in patients requiring a longer duration of dialysis [6]. Our study differed from these previous studies in that it included patients receiving kidneys The Author Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. 1
2 from DCD donors and more expanded criteria (ECD) donors than the early study, in keeping with the demographics of the donor population in most North American and European programs today. We hypothesize that a longer length of TND portends a poorer prognosis for long-term renal function in terms of creatinine clearance (CrCl) at 1 year. Also, recent publications [7, 8] have documented a better prognosis for DCD kidneys with DGF than for non-dcd kidneys with DGF, and we wished to examine the effect of a longer TND on function in these DCD kidneys. MATERIALS AND METHODS This was a retrospective chart review involving collaboration between the Western University (WU) and the Saskatchewan renal transplant program (SRTP). Information about each recipient and their donor as well as investigations in the preoperative and postoperative course of these 83 patients with DGF was collected retrospectively. Patients were divided into three groups depending on TND [group 1: <7 days (n = 52), group 2: 7 14 days (n = 13) and group 3 (n = 18): >14 days], but analysis was also carried out using TND as a linear variable. Our main outcome of interest was the CrCl at 1 year, and secondary outcomes were adverse events. CrCl was estimated using the Cockcroft Gault equation. Complications examined included wound infection or leakage, reoperation, ICU admission, readmission or graft loss within less than a year. Wound infection was defined as the need for the incision to be reopened partially or completely and packed. Significant wound leakage was defined as a need for consultation to a specialized wound care team or the placement of a bag appliance. Reoperations for the purpose of our study included only those reoperations that required reopening the kidney transplant incision. Neither program performed routine protocol biopsies, but instead performed biopsies based on clinical indication; rejection episodes in this study were biopsy proven. Univariate analysis of factors involved in CrCl at 1 year was carried out and factors with P < 0.20 were included in the multivariate analysis as per the classic method of Kleinbaum et al.[15]. The multivariate analysis was repeated to include variables that are generally considered classic confounders, including donor age [16], early acute rejection [17] and DCD donor, in addition to TND. Cold ischemic time (CIT), one of the traditional confounders, was not included because the range of CIT was very narrow and the difference between the donor kidneys with the longest and shortest CIT s would not be expected to make a significant difference to renal function [18], and in order to keep the number of variables to an acceptable number. Medications used postoperatively were not included in the model because all but one patient received induction (61 thymoglobulin, 21 basiliximab, 1 patient refused); no differences were found between the two types of induction with respect to CrCl at 1 year. Finally, all but three of the patients received tacrolimus-based immunosuppression, precluding any meaningful analysis of the effect of immunosuppressive drugs as a confounder. Biopsy-proven early acute rejection was included as a possible confounder in one of the regression models because of a trend towards less early acute rejection in the DCD group and because of this well-documented factor in the outcome of kidney transplants. Due to concerns over colinearity between donor age and donor Cr (r = 0.206, P = 0.05), these two could not be included in any model at the same time, but were analyzed individually in separate multivariate models. TND was analyzed in multivariate regression models first as a continuous variable, then as a categorical variable. Data were analyzed using SPSS 20.0 (IBM Corporation, Armonk, NY), including multivariate linear regression, the χ 2 - test, ANOVA, and Student s t-test with Bonferroni correction for multiple comparisons. Ethics approval was obtained from the Ethics Review Board at both institutions. RESULTS Between January 2004 and December 2011, there were 567 kidney transplants at WU Renal Transplant Program of London, Ontario and 227 at SRTP, for a total of 774 transplants. For the purposes of our study, multi-visceral, repeat and en bloc kidney transplants were excluded. A total of 83 patients receiving deceased donor kidney transplants developed DGF, which is defined as the need for dialysis in the first week posttransplant. There were 59 cases of DGF at WU and 24 cases of DGF at SRTP during this time period. The two sites had similar practices and, aside from the fact that the WU site has had a DCD program since 2006 and the SRTP does not have a DCD program, the two sites showed no significant differences in terms of donor or recipient age, dialysis modality, use of machine cold perfusion, CIT rate of DGF, rate of early acute rejection and length of stay. Patient demographics are shown in Table 1. The 83 patients with DGF were divided into three groups based on the number of days postoperatively that dialysis was needed, whether <7 days (group 1, n = 52), between 7 and 14 days (group 2, n = 13) and >2 weeks (group 3, n = 18). The three groups were similar in terms of recipient demographics, dialysis modality, proportion of DCD transplants and CIT. The CrCl at 30 days and at 1 year showed differences between the three groups, with poorer function seen in patients having longer TND. A greater proportion of patients with one or more complications were seen in the groups of patients requiring longer time on dialysis. Univariate analysis of potential predictors of CrCl at 1 year is shown in Table 2. A multivariate regression model of CrCl at 1 year was constructed including the variables with P- value < 0.20 on univariate analysis (donor age, DCD kidneys and TND). TND and DCD donor emerged as highly significant predictive factors of CrCl at 1 year (each with P < 0.001, Table 3). A longer TND predicted a lower CrCl and a patient receiving a DCD donor kidney would be expected to have a higher CrCl at 1 year. 2 C. Marek et al.
3 Table 1. Demographics and outcomes for the three groups of patients, divided according to TND Group 1 (<7 days) (n = 52) Group 2 (7 14 days) (n = 13) Group 3 (>14 days) (n = 18) P-value Total (n = 83) M:F 41:11 12:1 12: a 65:18 Recipient age (±SEM) 54.5 ± ± ± b 54.8 ± 1.4 Donor age (±SEM) 47.1 ± ± ± b 47.4 ± 1.6 Type of RRT (HD:PD) 39 : : 2 15 : a 65 : 18 DCD kidney 24 (46%) 5 (38%) 6 (33%) 0.62 a 35 (42%) Machine cold 18 (35%) 3 (28%) 7 (39%) 0.64 a 28 (34%) perfusion CIT (min ±SEM) 788 ± ± ± b 764 ± 42 TND (days ± SEM) 3.7 ± ± ± 5.6 <0.001 c 10.9 ± 1.8 Number of dialysis 2.3 ± ± ± 2.4 <0.001 b 5.0 ± 0.7 runs Length of stay 15.3 ± ± ± b 17.8 ± 1.1 (days ± SEM) One or more 13 (25%) 7 (54%) 13 (72%) (40%) complications d CrCl at 30 days (cc/min ± SEM) 42.5 ± ± ± 2.2 <0.001 b CrCl at 1 year (cc/min ± SEM) 56.7 ± ± ± b RRT, renal replacement therapy. a Calculated using the χ 2 -test. b Calculated using ANOVA. c Calculated using ANOVA, Kaplan Meier, and Krushkal Wallis. The result was the same for all three tests. d Composite of wound leak, wound infection, ICU admission, reoperation, graft loss under 1 year and death <1 year posttransplant. Table 2. Univariate analysis of factors predictive of CrCl at 1 year Factor P-value Donor age 0.02 Donor Cr 0.68 DCD kidney Use of machine cold perfusion 0.29 CIT 0.73 Thymoglobulin use 0.53 Hemodialysis 0.96 TND Acute rejection episode in first 30 days 0.28 The multivariate analysis was repeated using variables that are generally considered to be classic confounders. The result of the model including donor age, early acute rejection, DCD Table 3. Multivariate regression model of CrCl at 1 year Factor P-value Β 95% CI TND < , 0.24 DCD donor < , 27.6 Donor age 0.54 donor and TND was the same, with TND and DCD donor being highly significant predictors of CrCl at 1 year (each P < 0.001). Donor age and donor creatinine, which showed significant colinearity, were entered separately in multivariate models and again the results were the same. Likewise, when TND was entered as a categorical value in the models mentioned above, the results were unchanged. Comparison between patients with DGF who received a kidney from a DCD donor versus a non-dcd donor was carried out (Table 4). The two groups were similar in terms of demographics except for machine cold perfusion use 3 Time needed on dialysis in DGF
4 Table 4. Comparison of patients with DGF who received a DCD kidney transplant or a non-dcd kidney transplant Non-DCD (n = 48) DCD (n = 35) P-value Recipient age (±SEM) 53.8 ± ± a Donor age (±SEM) 47.7 ± ± a ECD 18 (38%) 9 (26%) 0.26 b Machine cold perfusion 12 (25%) 16 (46%) 0.05 b CIT (min) 660 ± ± a TND (days ± SEM) 12.5 ± ± a Number of dialysis runs 5.1 ± ± a Length of Stay (days ± SEM) 18.4 ± ± a CrCl at 30 days (cc/min ± SEM) 38.0 ± ± a CrCl at 1 year (cc/min ± SEM) 45.7 ± ± 4.0 <0.001 a Dialysis dependence at 30 days 8 (17%) 1 (3%) 0.10 b Rejection in first 30 days 9 (19%) 2 (6%) 0.06 b Readmission in first 6 months 24 (50%) 4 (11%) b Graft Loss before 1 year 4 (8%) b Death before 1 year 2 (4%) 1 (3%) 0.78 b One or more complications c 23 (48%) 10 (29%) 0.08 b DCD, donation after cardiac death; CIT, cold ischemic time. a Calculated using Student s t-test. b Calculated using the χ 2 -test. c Composite of wound leak, wound infection, ICU admission, reoperation, graft loss under 1 year and death <1 year posttransplant. (P = 0.05). While the CrCl was very similar for the two groups at 30 days, a marked difference was seen at 1 year, with the DCD, DGF group having a higher CrCl (63.7 versus 45.7 cc/ min, P < 0.001). A comparison of the adverse events sustained by patients in the two groups (Table 4) showed a difference in terms of readmissions in the first 6 months (50 versus 11%, non-dcd versus DCD). There was a trend towards more early acute rejection, graft loss and complications in the non-dcd DGF patients. DISCUSSION In our study of patients with DGF, the length of TND before the resolution of DGF was shown to be a factor predictive of CrCl at 1 year. Also, patients with DGF whose kidney transplants came from DCD donors had better CrCl at 1 year compared with patients with DGF whose kidneys did not come from DCD donors. Although DCD kidneys have a high incidence of DGF, it is becoming clear that DCD kidneys with DGF have similar creatinine at 1 year compared with standard criteria donors or DCD donor transplants that did not experience DGF [9, 10]. Markedly lower readmission rates were seen for recipients of DCD kidneys and (although not statistically significant), we saw trends towards less TND, lower early acute rejection, lower complication rates and lower readmission rates for the DCD group, similar to that in previous reports and arguing in favor of different mechanisms for DGF in the two groups. One possibility is that DCD donors are more carefully selected, but our data in Table 4 shows the DCD and non-dcd kidneys to have similar demographics. It has been hypothesized that there exist different mechanisms for the injury that leads to DGF whether a kidney is from a DCD donor or a donation after brain death (DBD) donor. In the case of DBD, inflammatory mediators and cytokines released due to the mechanism of death may increase inflammation and tissue injury [11]. Early diminished allograft reserve may then explain the long-term diminished GFR. On the other hand, the ischemic injury that occurs to DCD kidneys may be less likely to provoke immune attack and early acute rejection and more likely to be reversible. The reason for the association of prolonged TND with worse long-term function could be that more dialysis is somehow detrimental to long-term renal function, either because of transient hypotension that occurs with hemodialysis or to inflammatory reactions to dialysis membranes or dialysate [12, 13]. In our study, there was no difference in CrCl at 1 year between patients dialyzed postoperatively with peritoneal dialysis or with hemodialysis (56.0 ± 6.3 cc/min versus 4 C. Marek et al.
5 53.1 ± 2.5 cc/min, P = 0.27). An earlier study found that a single dialysis run in the early postoperative period resulted in no detrimental effect to long-term kidney function [6]. Instead, it seems more likely that the association between prolonged TND and decreased long-term function is due to the fact that kidneys with worse baseline function also have less functional reserve or perhaps fewer glomeruli [14] and hence require more support in terms of dialysis. The fact that increased donor age is associated with worse function at 1 year is in keeping with this possibility [7]. Our study is limited by the somewhat subjective nature of the definition of DGF. If and when to initiate dialysis as well as when to stop doing dialysis on these patients is somewhat of a subjective judgment call of the treating transplant physician, but is thought to be similar between the two sites. Thus, the number of days needed on dialysis (TND) is a rough measure at best, yet there is no denying that a patient who needed dialysis for the first 14 days postoperatively needed significantly more support than a patient who needed 5 days, for example. When the kidney wakes up out of DGF, however, it generally does so quite convincingly and it is likely that two transplant physicians might differ only by one dialysis treatment, if there was a difference at all. We used well-documented variables to construct our regression models, in order to control for known factors, yet any regression study is limited by the fact that a number of variables are likely unknown. CIT, one of the usual known factors, for example, did not emerge as a significant predictor likely because the average CIT s was quite reasonable and the range of CIT s was quite narrow. Early acute rejection, a classic confounder, did not emerge as a statistically significant confounder, and this may be related to the fact that neither center does protocol biopsies nor is there a protocol dictating how many days of lack of return of function warrants a biopsy. Only 30 out of 83 (36%) of the patients in our study had a transplant biopsy, with 12 done in the first week, 10 in the second week, and 8 after a period of >2 weeks from the time of the transplant. The incidence of early acute rejection may have been underestimated in our study as a result. A trend towards more early acute rejection in the non-dcd transplants in our study and literature showing significant differences between non-dcd and DCD transplants in terms of early acute rejection [13] further emphasizes the need for inclusion of early acute rejection in a multivariate analysis model. The proportion of patients experiencing one or more complications seems to increase with increased TND. Whether this is a cause or an effect of the increased TND cannot be discerned in this study, but it is nonetheless an interesting finding. In both centers, DGF is an indication to hold off the use of calcineurin inhibitors and to use thymoglobulin in the initial postoperative period. The use of thymoglobulin has been associated with leaky capillaries, hypotension, respiratory embarrassment and an increased risk of ICU admission, all of which may contribute to prolonging DGF. One of our earlier studies found that a large number of patients requiring ICU admission after transplant had received thymoglobulin [8]. The dosing and duration of thymoglobulin administration are protocol based and, according to our data, there is no difference in dose received whether someone had DGF for 5 or 21 days. The length of time it takes for a kidney to recover from DGF can provide useful prognostic information about longterm function, and it seems that the need for prolonged dialysis is more likely an effect than a cause of a reduced function kidney. DGF that lasts >2 weeks results in a markedly poorer function at 1 year. As the length of time on dialysis seems to be an effect rather than a cause of decreased function, early weaning from dialysis prior to definite return of renal function would not be expected to lead to an improvement in renal function. The differences between patients with DGF from DCD and non-dcd kidneys suggest a different mechanism of injury between the two types of organs and perhaps looking at interventions aimed at reducing the inflammatory response that occurs at the time of procurement of non-dcd kidneys should be pursued. ACKNOWLEDGEMENTS The authors thank Michael Bloch (WU), Corinne Weernink (WU), Sandra Lockhart (SRTP) and Verna Bloom (SRTP) for help in data collection and Dr Rhonda Bryce and Dr Punam Pahwa for their help with the statistics. C.M. supported by the University of Saskatchewan College of Medicine Dean s Research Program and the Department of Surgery Research Chair Funding. AUTHOR S CONTRIBUTION C.M. participated in study design, data collection, data analysis and writing of the paper. B.T. participated in study design, data collection, data analysis and writing of the paper. A.S. participated in study design and writing of the paper. P.P.L. participated in study design, data analysis and writing of the paper. M.A.J.M. participated in study design, data collection, data analysis and writing of the paper. REFERENCES 1. Yarlagadda SG, Klein CL, Jani A. Long term renal outcomes after DGF. Adv Chr K Dis 2008; 15: Perico N, Cattaneo D, Sayegh M et al. Delayed graft function in kidney transplantation. Lancet 2004; 364: Ojo AO, Wolfe RA, Held P et al. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997; 63: Giral-Classe M, Hourmant M, Cantarovich D et al. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. Kidney Int 1998; 54: Dominguez J, Lira F, Rebodello R et al. Duration of delayed graft function is an important predictor of 1-year serum Creatinine. Transpl Proc 2009; 41: Jayaram D, Kommareddi M, Sung RS et al. Delayed graft function requiring more than one-time dialysis treatment is associated 5 Time needed on dialysis in DGF
6 with inferior clinical outcomes. Clin Transplant 2012; 26: E536 E Weinstein JR, Anderson S. The aging kidney: physiological changes. Adv Chronic Kidney Dis 2010; 17: Moser M, Sharpe M, Weernink C et al. Five-year experience with donation after cardiac death kidney transplantation in a Canadian transplant program: factors affecting outcomes. Cdn Urol Assoc J 2012; 6: Singh RP, Farney AC, Rogers J et al. Kidney transplantation from donation after cardiac death donors: lack of impact of delayed graft function on post-transplant outcomes. Clin Transplant 2011; 25: Nagaraja P, Roberts GW, Stephens M et al. Influence of delayed graft function and acute rejection on outcomes after kidney transplantation from donors after cardiac death. Transplantation 2012; 94: Stroo I, Stokman G, Teske GJ et al. Chemokine expression in renal ischemia/reperfusion is most profound during the reparative phase. Int Immunol 2010; 22: Bitla AR, Reddy PE, Manohar SM, et al. Effect of a single hemodialysis session on inflammatory markers. Hemodial Int 2010; 14: Jofre R, Rodriguez-Benitez P, Lopez-Gomez JM et al. Inflammatory syndrome in patients on hemodialysis. JASN 2006; 17: S274 S Nyengaard JR, Bendtsen TF. Glomerular number and size in relation to age, kidney, and body surface in normal man. Anat Rec 1992; 232: Kleinbaum DG, Kupper LL, Muller KE et al. Applied Regression Analysis and Other Multivariable Methods, 3rd edn. Belmont, CA: Wadsworth, 1998, pp Saidi RF, Elias N, Kawai T et al. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant 2007; 7: McLaren AJ, Jassem W, Gray DW et al. Delayed graft function: risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transpl 1999; 13: Layler LK, Srinivas TR, Schold JD. Influence of CIT-induced DGF on kidney transplant outcomes. Am J Transplant 2011; 11: Received for publication: ; Accepted in revised form: C. Marek et al.
Donor Kidney Recovery Methods and the Incidence of Lymphatic Complications in Kidney Transplant Recipients
Donor Kidney Recovery Methods and the Incidence of Lymphatic Complications in Kidney Transplant Recipients The Harvard community has made this article openly available. Please share how this access benefits
More informationDeceased-Donor Renal Transplant Information for patients
Deceased-Donor Renal Transplant Information for patients Exceptional healthcare, personally delivered As part of the work-up for the NHS Blood and Transplant (NHSBT) kidney transplant waiting list, you
More informationWhere Will my New Kidney Come From?
Where Will my New Kidney Come From? The Organ Shortage There is a severe shortage of organs for transplant. This means that the wait for a kidney transplant can be many years. The UW Transplant Program
More informationTHE BENEFITS OF LIVING DONOR KIDNEY TRANSPLANTATION. feel better knowing
THE BENEFITS OF LIVING DONOR KIDNEY TRANSPLANTATION feel better knowing your choice will help create more memories. Methods of Kidney Donation Kidneys for transplantation are made available through deceased
More informationOmega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9
Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer
More informationElevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality
Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality C. Tomas, MA Castel, E Roig, I. Vallejos, C. Plata, F. Pérez-Villa Cardiology Department,
More information*6816* 6816 CONSENT FOR DECEASED KIDNEY DONOR ORGAN OPTIONS
The shortage of kidney donors and the ever-increasing waiting list has prompted the transplant community to look at different types of organ donors to meet the needs of our patients on the waiting list.
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationWake Forest School of Medicine Department of General Surgery
Wake Forest School of Medicine Department of General Surgery TRANSPLANT SURGERY RESIDENT CURRICULUM (PGY-3) OVERVIEW This curriculum has largely been adapted from the curriculum for transplant surgery
More informationThe sensitive marker for glomerular filtration rate (GFR) Estimation of GFR from Serum Cystatin C:
The sensitive marker for glomerular filtration rate (GFR) Estimation of GFR from Serum Cystatin C: The good correlation allows close estimation of GFR Cystatin C GFR GFR in serum estimated* measured* n
More informationQuestions and Answers for Transplant Candidates about the New Kidney Allocation System
TA L K I N G A B O U T T R A N S P L A N TAT I O N U N I T E D N E T W O R K F O R O R G A N S H A R I N G Questions and Answers for Transplant Candidates about the New Kidney Allocation System United
More informationChapter 24: Renal Transplantation in the Older Adult
Chapter 24: Renal Transplantation in the Older Adult Erica L. Hartmann Abdominal Organ Transplant Program, Department of Internal Medicine-Nephrology, Wake Forest University Health Sciences, Winston-Salem,
More informationNew Kidney Allocation and What it Means to Your Transplant Center and Your Patients
New Kidney Allocation and What it Means to Your Transplant Center and Your Patients Alexander Wiseman, M.D. Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas
More informationKidneys. Kidney Failure4. Transplantation
Kidneys & Kidney Failure4 Transplantation This booklet helps you understand the process of transplantation. It defines the criteria for a donor and the recipient. It also clearly explains the concepts
More informationANNUAL REPORT ON KIDNEY TRANSPLANTATION
ANNUAL REPORT ON KIDNEY TRANSPLANTATION REPORT FOR 2013/2014 (1 APRIL 2004 31 MARCH 2014) PUBLISHED SEPTEMBER 2014 PRODUCED IN COLLABORATION WITH NHS ENGLAND Contents 1 Executive Summary... 1 2 Introduction...
More informationKidney Transplantation
ilearning about your health Kidney Transplantation www.cpmc.org/learning What is Kidney Failure? Normally, kidneys filter waste products from your blood, control the balance of salt and water in your body,
More informationKidney and Pancreas Transplant Evaluation Clinics and Committee: Inpatient Nephrology Transplant Consult Service
Care of Renal Transplant Patients takes place in five distinct practice settings at the University of Michigan: a) Kidney and Pancreas Pre-transplant evaluation clinics (five half-day clinics per week)
More informationrenal transplantation: A single-center comparative study
Impact of posterior urethral valves on pediatric renal transplantation: A single-center comparative study BY Mohamed Kamal Gheith, MD Oberarzt die Urologie, Universitätsmedizin Mainz Ass. Prof. of Urology,
More informationThe New Kidney Allocation System: Resources for Protocols and Processes webinar.
The New Kidney Allocation System: Resources for Protocols and Processes webinar. 1 Speakers for the webinar are: Dr. Richard Formica Associate Professor of Medicine and Surgery, Yale University School
More informationHow does a kidney transplant differ from dialysis?
TA L K I N G A B O U T T R A N S P L A N TAT I O N Frequently Asked Questions about Kidney Transplant Evaluation and Listing If your kidneys have stopped working properly, or may stop working soon, you
More informationGFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working
GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National
More informationCanadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2003 to 2012
Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2003 to 2012 Types of Care Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate
More informationSaint Francis Kidney Transplant Program Issue Date: 6/9/15
Kidney Transplant Candidate Informed Consent Education Here are educational materials about Kidney Transplant. Please review and read these before your evaluation visit. The RN Transplant Coordinator will
More informationHigh Blood Pressure and Your Kidneys
American Kidney Fund reaching out giving hope improving lives High Blood Pressure and Your Kidneys reaching out giving hope improving lives High Blood Pressure: The #2 Cause of Kidney Failure Your doctor
More informationHeart transplantation
Heart transplantation A patient s guide 1 Heart transplantation Heart transplantation has the potential to significantly improve the length and quality of life for patients with severe heart failure.
More informationModels of Chronic Kidney Disease Care and Initiation of Dialysis. Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK
Models of Chronic Kidney Disease Care and Initiation of Dialysis Dr Paul Stevens Kent Kidney Care Centre East Kent Hospitals, UK Early Crash Landings Talk Outline Pathways & Definitions Guideline recommendations
More informationIs a Kidney Transplant Right for Me?
Is a Kidney Transplant Right for Me? Network 8 Introduction What do singer Natalie Cole, actor Ken Howard, funny men Tracy Morgan and George Lopez and fashion reporter Steven Cojocaru have in common? They
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationMaintenance Steroid Avoidance in Pediatric Heart Transplantation is Associated with Excellent Graft Survival
Maintenance Steroid Avoidance in Pediatric Heart Transplantation is Associated with Excellent Graft Survival Scott Auerbach, MD, Jane Gralla, PhD, Shelley Miyamoto, MD, David Campbell, MD, and Biagio Pietra,
More information10. Treatment of peritoneal dialysis associated fungal peritonitis
10. Treatment of peritoneal dialysis associated fungal peritonitis Date written: February 2003 Final submission: July 2004 Guidelines (Include recommendations based on level I or II evidence) The use of
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationEstimated GFR Based on Creatinine and Cystatin C
Estimated GFR Based on Creatinine and Cystatin C Lesley A Stevens, MD, MS Tufts Medical Center, Tufts University School of Medicine Boston MA Chronic Kidney Disease-Epidemiology Collaboration UO1 DK 053869,
More informationExpanded criteria donors for kidney transplantation
American Journal of Transplantation 2003; 3 (Suppl. 4): 114 125 Blackwell Munksgaard 2003 Blackwell Munksgaard ISSN 1601-2577 Expanded criteria donors for kidney transplantation Robert A. Metzger a, Francis
More informationDeceased Organ Donor Potential in Canada
Report December 2014 Factors Influencing Health Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of comprehensive and integrated health
More informationCurrent Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, 2011 - ESRD Registry Committee, Korean Society of Nephrology*
Current Renal Replacement Therapy in Korea - Insan Memorial Dialysis Registry, 2011 - ESRD Registry Committee, Korean Society of Nephrology* =Abstracts= Registry committee of Korean Society of Nephrology
More informationKidney Transplant Program. Guide to Understanding Transplant
Kidney Transplant Program Guide to Understanding Transplant The wonderful physicians and staff of the Stanford Kidney Transplant Program are always there to contact if I have a question or concern. They
More informationFive things to watch in nephrology. David Sheikh-Hamad, MD Professor of Medicine, Molecular & Cellular Biology Baylor College of Medicine
Five things to watch in nephrology David Sheikh-Hamad, MD Professor of Medicine, Molecular & Cellular Biology Baylor College of Medicine Financial Disclosures David Sheikh-Hamad, MD In the context of my
More informationJames F. Kravec, M.D., F.A.C.P
James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice
More informationKidney Disease WHAT IS KIDNEY DISEASE? TESTS TO DETECT OR DIAGNOSE KIDNEY DISEASE TREATMENT STRATEGIES FOR KIDNEY DISEASE
Kidney Disease WHAT IS KIDNEY DISEASE? Kidney disease is when your kidneys are damaged and not functioning as they should. When kidney disease is not going away it is called chronic kidney disease or CKD.
More informationImpact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005. Tania Tang PHASE Symposium May 12, 2007
Impact of Diabetes on Treatment Outcomes among Maryland Tuberculosis Cases, 2004-2005 Tania Tang PHASE Symposium May 12, 2007 Presentation Outline Background Research Questions Methods Results Discussion
More informationLong-term outcome of third kidney transplants
Nephrol Dial Transplant (27) 22: 2693 27 doi:1.193/ndt/gfm226 Advance Access publication 23 April 27 Original Article Long-term outcome of third kidney transplants Alexandre Loupy 1, Dany Anglicheau 1,
More informationYour Kidneys: Master Chemists of the Body
Your Kidneys: Master Chemists of the Body www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundation's Kidney Disease Outcomes
More informationNierfunctiemeting en follow-up van chronisch nierlijden
Nierfunctiemeting en follow-up van chronisch nierlijden 12 Jan 2016 Patrick Peeters, M.D. Dept Nephrology Ghent University Hospital Plan of presentation 1/ Renal function determination: Measured GFR Estimated
More informationNOTICE TO THE INDIVIDUAL SIGNING THE ILLINOIS POWER OF ATTORNEY FOR HEALTH CARE
NOTICE TO THE INDIVIDUAL SIGNING THE ILLINOIS POWER OF ATTNEY F HEALTH CARE No one can predict when a serious illness or accident might occur. When it does, you may need someone else to speak or make health
More informationMedicine & Emergency Department Pre-transplantation decisions and preparation
Medicine & Emergency Department Pre-transplantation decisions and preparation Information for renal patients Who can have a kidney transplant? Kidney transplantation is the preferred choice of treatment
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationSeries 1 Case Studies Adverse Events that Represent Unanticipated Problems: Reporting Required
Welcome! This document contains three (3) series of Case Study examples that will demonstrate all four OHSU reporting categories (#1 4) as well as examples of events that are considered not reportable.
More information1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:
1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance
More informationCHRONIC KIDNEY DISEASE MANAGEMENT GUIDE
CHRONIC KIDNEY DISEASE MANAGEMENT GUIDE Outline I. Introduction II. Identifying Members with Kidney Disease III. Clinical Guidelines for Kidney Disease A. Chronic Kidney Disease B. End Stage Renal Disease
More informationPotential Adverse Effects of Low Dose Aspirin and Diuretic Drug Combination on Kidney Function.
Potential Adverse Effects of Low Dose Aspirin and Diuretic Drug Combination on Kidney Function. Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author s address and current
More informationWilliam B. Schwartz Division of Nephrology Fellowship Training Program Curriculum
William B. Schwartz Division of Nephrology Fellowship Training Program Curriculum Consult/Transplant Servic Patient Care Take medical history Perform physical examination Urinalysis and sediment eval Interpret
More informationThe Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome
Biomedical & Pharmacology Journal Vol. 6(2), 259-264 (2013) The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome Vadod Norouzi 1, Ali
More informationESRD FACILITY SURVEY (CMS-2744) INSTRUCTIONS FOR COMPLETION
ESRD FACILITY SURVEY (CMS-2744) INSTRUCTIONS FOR COMPLETION REPORTING RESPONSIBILITY The ESRD Facility Survey is designed to capture only a limited amount of information concerning each Federally approved
More informationIs a kidney transplant right for me?
Is a kidney transplant right for me? Your guide to the transplant process www.esrdncc.org Contents Introduction 3 What is a Transplant Center? 4 What is the Waiting List? 5 What Happens After the Surgery?
More informationSummary HTA. HTA-Report Summary. Introduction
Summary HTA HTA-Report Summary Antioxidative vitamines for prevention of cardiovascular disease for patients after renal transplantation and patients with chronic renal failure Schnell-Inderst P, Kossmann
More informationKIDNEY TRANSPLANTATION. The Most Commonly Asked Questions About Transplantation
Chapter 12 KIDNEY TRANSPLANTATION A Guide for Patients Brigham & Women s Hospital Kidney Transplant Staff * The Most Commonly Asked Questions About Transplantation What is a kidney transplant? A kidney
More informationRenovascular Hypertension
Renovascular Hypertension Philip Stockwell, MD Assistant Professor of Medicine (Clinical) Warren Alpert School of Medicine Cardiology for the Primary Care Provider September 28, 201 Renovascular Hypertension
More informationCPT Codes for Bone Marrow Transplant January 2015 James L. Gajewski, MD
The blood and marrow transplant field has 15 dedicated CPT codes. These CPT codes can be categorized into three groups: 1. Collection Codes 2. Cell Processing Codes 3. Cell Infusion Codes Collection Codes
More informationPANCREAS, PANCREAS-KIDNEY, SEGMENT OF PANCREAS AND ISLET PANCREATIC TISSUE TRANSPLANTATION SUR703.013
PANCREAS, PANCREAS-KIDNEY, SEGMENT OF PANCREAS AND ISLET PANCREATIC TISSUE TRANSPLANTATION SUR703.013 COVERAGE: A simultaneous or combined pancreas-kidney transplant (SPK) from a cadaver donor or a simultaneous
More informationAnticoagulation Dosing at UCDMC Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h
Indication Agent Standard Dose Comments and Dose Adjustments VTE Prophylaxis All Services UFH 5,000 units SC q 8 h See EMR adult VTE prophylaxis CI order set Enoxaparin See service specific dosing Assess
More informationPrognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
More informationKIDNEY PRE-TRANSPLANT EDUCATION BOOK
KIDNEY PRE-TRANSPLANT EDUCATION BOOK This book is to give information to you and your family about kidney transplant. Please keep this book handy in order to look back at it as you have questions. At the
More informationCONSENT FORM. Procedure: Descemet s Stripping Automated Endothelial Keratoplasty (DSAEK)
CONSENT FORM Procedure: Descemet s Stripping Automated Endothelial Keratoplasty (DSAEK) Surgeon: Jeffrey W. Liu, M.D. Peninsula Laser Eye Medical Group 1174 Castro Street, Ste. 100 Mountain View, CA 94040
More informationSolid Organ Transplantation
Solid Organ Transplantation Infection Prevention And Control Transplant Atlantic 2011 October 13/2011 Kathy Hart Introduction In the past several years, the drugs that we use, the surgeries themselves,
More informationCurrent Trends in the Use of Peritoneal Dialysis Catheters
Advances in Peritoneal Dialysis, Vol. 22, 2006 Dana Negoi, Barbara F. Prowant, Zbylut J. Twardowski The Tenckhoff catheter was developed in 1968 and has been widely used since for chronic peritoneal dialysis
More informationProtocol for the safe administration of iodinated contrast media in diagnostic radiology
Protocol for the safe administration of iodinated contrast media in diagnostic radiology Protocol statement: This protocol applies to all staff within Radiology Departments at Heart of England NHS Foundation
More informationThe effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic review and economic model
The effectiveness and cost-effectiveness of storing donated kidneys from deceased donors The effectiveness and cost-effectiveness of methods of storing donated kidneys from deceased donors: a systematic
More informationUnderstanding Treatment Options for Renal Therapy
Understanding Treatment Options for Renal Therapy Kidney failure happens to many different people for many different reasons 1 What causes kidney failure? Diabetes Chronic infection High blood pressure
More informationNBTA report on Black, Asian and Minority Ethnic Organ Donation and Transplantation data
NBTA report on Black, Asian and Minority Ethnic Organ Donation and Transplantation data July 0 Contents Page Supported by the Department of Health INTRODUCTION ORGAN DONOR REGISTER (ODR) DECEASED ORGAN
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationWhat does Hepatitis C mean to me as a CKD Patient?
What does Hepatitis C mean to me as a CKD Patient? Clinical Practice Guidelines for the Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in CKD Introduction Worldwide, about 170 million people
More informationResource Document 6: Tetanus Immunization. I. Introduction
Resource Document 6: Tetanus Immunization I. Introduction Attention must be directed to adequate tetanus prophylaxis in the multiply injured patient, particularly if open-extremity trauma is present. The
More informationOutcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital
More informationKidney Pre-Transplant Patient Education Handbook. Charles O. Strickler Transplant Center
Kidney Pre-Transplant Patient Education Handbook Charles O. Strickler Transplant Center Kidney Pre-Transplant Patient Education Handbook Charles O. Strickler Transplant Center Kidney Transplant Program
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationActive Clinical Trials
Active Clinical Trials 1. Genentech Efalizumab Protocol No. ACD4230g Title: A Phase II/III, Randomized, Open-Label, Active-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationOrgan and Tissue Donation: An Overview
Organ and Tissue Donation: An Overview E-learning module revised by LifeSource, 2012 This learning module is part of a series of e-learning modules designed to meet hospital education requirements for
More informationMANAGING ANEMIA. When You Have Kidney Disease or Kidney Failure. www.kidney.org
MANAGING ANEMIA When You Have Kidney Disease or Kidney Failure www.kidney.org About the Information in this Booklet Did you know that the National Kidney Foundation (NKF) offers guidelines and commentaries
More informationIntegrated Medical Record System for Nephrology
Integrated Medical Record System for Nephrology cyberren is a new generation, off-the-shelf renal clinical data management solution designed to address your clinical and administrative needs. cyberren
More informationIntroduction to Blood Management
Introduction to Blood Management What is Blood Management? Preventing a blood transfusion to the patient who doesn t need one Right blood product, at the right time, in the right dose, to the right patient
More informationAdvantages and disadvantages of CRRT in ARF patients. Norbert Lameire Renal Division University Hospital Ghent, Belgium
Advantages and disadvantages of CRRT in ARF patients Norbert Lameire Renal Division University Hospital Ghent, Belgium Alexandria, 17/2/2005 Indications for RRT in critically ill ARF patients Renal Replacement
More informationObjectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History
Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize
More informationDIALYSIS COMPACT. The function, diseases and treatments for the human kidney.
DIALYSIS COMPACT The function, diseases and treatments for the human kidney. Content 3 Editorial 4 What do healthy kidneys accomplish? 5 What causes kidney disease? 6 What effects does kidney disease have?
More informationPatient Information Booklet Kidney Transplantation. Cardiff Transplant Unit
Patient Information Booklet Kidney Transplantation Cardiff Transplant Unit Introduction You have been given this information booklet because your kidney specialist thinks you may benefit from a kidney
More informationApril 20, 2016. Dear Drs. Menikoff, Borror, and Puglisi:
April 20, 2016 Jerry Menikoff, M.D., J.D. Director and Kristina Borror, Ph.D. Director, Division of Compliance Oversight Office for Human Research Protections Department of Health and Human Services 1101
More informationINFORMED CONSENT FOR SLEEVE GASTRECTOMY
INFORMED CONSENT FOR SLEEVE GASTRECTOMY This informed-consent document has been prepared to help inform you about your Sleeve Gastrectomy including the risks and benefits, as well as alternative treatments.
More informationAcute on Chronic Liver Failure: Current Concepts. Disclosures
Acute on Chronic Liver Failure: Current Concepts Vandana Khungar, MD MSc Assistant Professor of Medicine University of Pennsylvania, Perelman School of Medicine September 20, 2015 None to declare Disclosures
More informationTECHNICAL/CLINICAL TOOLS BEST PRACTICE 7: Depression Screening and Management
TECHNICAL/CLINICAL TOOLS BEST PRACTICE 7: Depression Screening and Management WHY IS THIS IMPORTANT? Depression causes fluctuations in mood, low self esteem and loss of interest or pleasure in normally
More informationImmunosuppressive drugs
Immunosuppressive drugs RJM ten Berge Afd. Inw. Geneeskunde AMC contents overview targets mechanism of action Effects on immune capacity measured by responses to vaccination Immune response 1 calcineurin
More informationPRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators
Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Whan Lee, MD, PhD On behalf
More informationManaging Anemia When You Are on Dialysis. Stage 5
Managing Anemia When You Are on Dialysis Stage 5 What is anemia? Anemia happens when your red blood cells are in short supply. Red blood cells carry oxygen from your lungs to all parts of your body, giving
More information2.5mg SC daily. INR target 2-3 30 mg SC q 12 hr or 40mg daily. 10 mg PO q day (CrCl 30 ml/min). Avoid if < 30 ml/min. 2.
Anticoagulation dosing at UCDMC (SC=subcutaneously; CI=continuous infusion) Indication Agent Dose Comments Prophylaxis Any or No bleeding risk factors see adult heparin (VTE prophylaxis) IV infusion order
More informationDIABETES. Eyes, Heart, Nerves, Feet, and Kidneys. www.kidney.org
DIABETES Eyes, Heart, Nerves, Feet, and Kidneys www.kidney.org About the Information in this Booklet Did you know that the National Kidney Foundation (NKF) offers guidelines and commentaries that help
More informationImpact of MELD-Based Allocation on End-Stage Renal Disease After Liver Transplantation
American Journal of Transplantation 2011; 11: 2372 2378 Wiley Periodicals Inc. C Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2011.03703.x
More information2014/15 National Tariff Payment System. Annex 7A: Specified services for acute services for local pricing
2014/15 National Tariff Payment System Annex 7A: Specified services for acute services for local pricing 17 December 2013 Publications Gateway Reference 00883 Annex 7A: Specified services for acute services
More informationMultivariate Logistic Regression
1 Multivariate Logistic Regression As in univariate logistic regression, let π(x) represent the probability of an event that depends on p covariates or independent variables. Then, using an inv.logit formulation
More informationMedicare Coverage of Kidney Dialysis and Kidney Transplant Services
CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Coverage of Kidney Dialysis and Kidney Transplant Services If you have permanent kidney failure, this official government booklet explains the following:
More informationContinuous Renal Replacement Therapy. Jai Radhakrishnan, MD, MS
Continuous Renal Replacement Therapy Jai Radhakrishnan, MD, MS History of the CRRT program 1988 Open heart program Active transplant program Deep dissatisfaction with peritoneal dialysis in hemodynamically
More information